

## ALLIGATOR BIOSCIENCE ANNOUNCES CAPITAL MARKETS DAY 2023

Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces it will hold a Capital Markets Day on December 1, 2023. The event will be hosted by members of Alligator's executive management team who will provide an overview of the Company's strategy, its proprietary and partnered assets, and its technology platforms.

### Capital Markets Day Details

- Date/Time: Friday, December 1, 2023 at 2:00 PM CET / 8:00 AM EST
- Location: 7A Posthuset, Vasagatan 28, Stockholm, Sweden
- Format: In-person event to be streamed live

To attend the event in person, contact IR & Communications Manager, Greta Eklund, at [ir@alligatorbioscience.com](mailto:ir@alligatorbioscience.com). Please note that the number of seats is limited.

The event will be live-streamed to Alligator's Youtube channel, accessible [through this link](#).

### Capital Markets Day Agenda

- **Overview of Alligator Bioscience:** Chief Executive Officer Søren Bregenholt will present an overview of the Company's strategic direction and its proprietary and partnered assets
- **Lead Asset Mitazalimab:** Chief Medical Officer Dr. Sumeet Ambarkhane will provide an update on the clinical data generated so far by mitazalimab along with a broader view of the Company's CD40 program
- **Key Opinion Leader:** Dr. Gregory Beatty, Associate Professor of Medicine at the University of Pennsylvania, will explain the current treatment landscape for pancreatic cancer and the potential of mitazalimab to change the treatment paradigm
- **Alligator's Technology Platforms:** Chief Technology Officer Laura von Schantz will discuss Alligator's proprietary technology platforms Neo-X-Prime™ and Ruby™, including the pivotal role Ruby™ is playing in Alligator's research collaboration and license agreement with Orion Corporation
- **ATOR-4066:** Chief Scientific Officer Peter Ellmark will look at the progress Alligator is making with ATOR-4066, a third generation bispecific antibody targeting CD40 and CEACAM5, developed by the Company's Neo-X-Prime™ platform

**PRESS RELEASE**

31 October 2023 13:00:00 CET



- **4-1BB:** Chief Medical Officer Dr. Sumeet Ambarkhane will provide the latest updates on ATOR-1017, Alligator's 4-1BB monoclonal antibody with best-in-class potential, and ALG.APV-527, a bispecific antibody with a tumor-directed 4-1BB agonistic effect being co-developed with Aptevo Therapeutics

Live question and answer sessions will be held after each presentation and CEO Søren Bregenholt will provide concluding remarks and present Alligator's strategic outlook at the end of the event.

**For further information, please contact:**

---

Søren Bregenholt, CEO

E-mail: [soren.bregenholt@alligatorbioscience.com](mailto:soren.bregenholt@alligatorbioscience.com)

Phone: +46 (0) 46 540 82 00

LifeSci Advisors

Investor Relations

Guillaume van Renterghem

E-mail: [gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)

Phone: +41 (0) 76 735 01 31

**About Alligator Bioscience**

---

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit [alligatorbioscience.com](https://alligatorbioscience.com).

**Attachments**

---

**Alligator Bioscience Announces Capital Markets Day 2023**